PVLA
Palvella Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Palvella Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Largest filed tie
0
filed ties
Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases. Palvella Therapeutics is headquartered in Wayne, Pennsylvania.
Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases. Palvella Therapeutics is headquartered in Wayne, Pennsylvania.
No other changes.
No other changes.
Last report2 of 6 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Annual filing, covered
10-K parsed · Mar 31 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 31 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Palvella Therapeutics, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Palvella Therapeutics, Inc.'s 6 closest co-movers, none share that code.
No trades yet today.
No trades yet today.
Palvella Therapeutics, Inc.
162.31
pre 163.00 +0.44%
Tall tick = annual report · Source: EDGAR
| Manager | Value | % base | |
|---|---|---|---|
| Suvretta | $173.5M | 7.79% | −1.57% |
| Jennison | $146.8M | 6.59% | +49.95% |
| BlackRockindex-like | $140.3M | 6.30% | +33.71% |
| Frazier Life Sciences | $134.8M | 6.06% | 0.00% |
| First Light | $118.0M | 5.30% | −21.30% |
| Manager | Value | % base | |
|---|---|---|---|
| Suvretta | $173.5M | 7.79% | −1.57% |
| Jennison | $146.8M | 6.59% | +49.95% |
| BlackRockindex-like | $140.3M | 6.30% | +33.71% |
| Frazier Life Sciences | $134.8M | 6.06% | 0.00% |
| First Light | $118.0M | 5.30% | −21.30% |
Bull2
Bear1
Expected move
Inputs8Q avg ±5.8%·×0.77·cheap
straddle ±8.2%
spot 162.28exp Nov 20ATM strike 160ATM straddle 15.75IV 58%